THE US Food and Drug
Administration has approved the
first generic version of the cancer
drug Doxil (doxorubicin
hydrochloride liposome injection).
The drug is currently on the FDA’s
drug shortage list, with the
approval of the generic aiming to
help resolve the shortfall.
A year ago the FDA allowed
temporary controlled importation
of Lipodox as an alternative to
Doxil, despite the drug not being
approved in the USA.
The generic version is made by
Sun Pharma Global, and once
supplies of the new product are
sufficient to meet projected
demand, the unapproved item will
no longer be able to be imported.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Feb 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Feb 13
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.